{"component": "definition", "props": {"groups": [{"snippet": "means any upfront or similar payments made during the period of twelve months ending on the Closing Date or arising thereafter in connection with any drug or pharmaceutical product research and development or collaboration arrangements or the closing of any Drug Acquisition.", "snippet_links": [{"key": "payments-made", "type": "clause", "offset": [29, 42]}, {"key": "period-of", "type": "definition", "offset": [54, 63]}, {"key": "twelve-months", "type": "clause", "offset": [64, 77]}, {"key": "the-closing-date", "type": "clause", "offset": [88, 104]}, {"key": "in-connection-with", "type": "clause", "offset": [127, 145]}, {"key": "product-research-and-development", "type": "clause", "offset": [173, 205]}, {"key": "collaboration-arrangements", "type": "clause", "offset": [209, 235]}, {"key": "drug-acquisition", "type": "definition", "offset": [258, 274]}], "size": 42, "samples": [{"hash": "2zRiOiKvoVs", "uri": "/contracts/2zRiOiKvoVs#upfront-payments", "label": "Credit Agreement (Jazz Pharmaceuticals PLC)", "score": 35.9021224976, "published": true}, {"hash": "5HWjOaqYSKc", "uri": "/contracts/5HWjOaqYSKc#upfront-payments", "label": "Credit Agreement (Jazz Pharmaceuticals PLC)", "score": 35.5544166565, "published": true}, {"hash": "1i4pnTrsiEt", "uri": "/contracts/1i4pnTrsiEt#upfront-payments", "label": "Credit Agreement (Jazz Pharmaceuticals PLC)", "score": 35.0643386841, "published": true}], "hash": "84de6f5d3684579708043e1dd6dfbd2b", "id": 1}, {"snippet": "means any upfront or similar payments made in connection with any drug or pharmaceutical product research and development or collaboration arrangements or the closing of any Drug Acquisition.", "snippet_links": [{"key": "payments-made", "type": "clause", "offset": [29, 42]}, {"key": "in-connection-with", "type": "clause", "offset": [43, 61]}, {"key": "product-research-and-development", "type": "clause", "offset": [89, 121]}, {"key": "collaboration-arrangements", "type": "clause", "offset": [125, 151]}, {"key": "the-closing", "type": "clause", "offset": [155, 166]}, {"key": "drug-acquisition", "type": "definition", "offset": [174, 190]}], "size": 14, "samples": [{"hash": "g0pfX5n6qkA", "uri": "/contracts/g0pfX5n6qkA#upfront-payments", "label": "Indenture (Bausch Health Companies Inc.)", "score": 33.1095123291, "published": true}, {"hash": "137GSb8F9SM", "uri": "/contracts/137GSb8F9SM#upfront-payments", "label": "Indenture (Bausch Health Companies Inc.)", "score": 32.433265686, "published": true}, {"hash": "6SdnEhtMDcF", "uri": "/contracts/6SdnEhtMDcF#upfront-payments", "label": "Indenture (Bausch Health Companies Inc.)", "score": 30.1800136566, "published": true}], "hash": "69d28aee1dff67bda2e9667fbae1ea35", "id": 2}, {"snippet": "means any upfront or similar payments made in connection with any drug or pharmaceutical product research and development or collaboration arrangements or the closing of any Permitted Acquisition or other acquisition (including any license or the acquisition of any license) of any rights in respect of any drug or other pharmaceutical product (and any related property or assets).", "snippet_links": [{"key": "payments-made", "type": "clause", "offset": [29, 42]}, {"key": "in-connection-with", "type": "clause", "offset": [43, 61]}, {"key": "product-research-and-development", "type": "clause", "offset": [89, 121]}, {"key": "collaboration-arrangements", "type": "clause", "offset": [125, 151]}, {"key": "the-closing", "type": "clause", "offset": [155, 166]}, {"key": "permitted-acquisition", "type": "definition", "offset": [174, 195]}, {"key": "other-acquisition", "type": "definition", "offset": [199, 216]}, {"key": "the-acquisition", "type": "clause", "offset": [243, 258]}, {"key": "in-respect-of", "type": "definition", "offset": [289, 302]}, {"key": "related-property", "type": "clause", "offset": [353, 369]}], "size": 13, "samples": [{"hash": "bJ2LImOo36a", "uri": "/contracts/bJ2LImOo36a#upfront-payments", "label": "Credit Agreement (Horizon Therapeutics Public LTD Co)", "score": 34.598903656, "published": true}, {"hash": "6m9HB1XrWD7", "uri": "/contracts/6m9HB1XrWD7#upfront-payments", "label": "Credit Agreement (Horizon Therapeutics Public LTD Co)", "score": 32.2005462646, "published": true}, {"hash": "1z3KHsseGm", "uri": "/contracts/1z3KHsseGm#upfront-payments", "label": "Credit Agreement (Horizon Therapeutics Public LTD Co)", "score": 30.9603004456, "published": true}], "hash": "9e68195f803568740e30f9a1889777c4", "id": 3}, {"snippet": "has the meaning set forth in Section 2.08.", "snippet_links": [], "size": 11, "samples": [{"hash": "a1gZMSCFy01", "uri": "/contracts/a1gZMSCFy01#upfront-payments", "label": "Amendment No. 2 to the Revolving Credit Agreement (Victoria's Secret & Co.)", "score": 36.3867225647, "published": true}, {"hash": "26SVTXKOQ5t", "uri": "/contracts/26SVTXKOQ5t#upfront-payments", "label": "Amendment to Revolving Credit Agreement (Bath & Body Works, Inc.)", "score": 36.3867225647, "published": true}, {"hash": "lOERwjj5Xat", "uri": "/contracts/lOERwjj5Xat#upfront-payments", "label": "Amended and Restated Revolving Credit Agreement (Bath & Body Works, Inc.)", "score": 34.6646118164, "published": true}], "hash": "9f739d1da8a5a39b99cf51b101b57bb3", "id": 4}, {"snippet": "means any upfront or similar payments made in connection with any drug or pharmaceutical product research and development or collaboration arrangements or the closing of any Permitted Investment or other acquisition (including any license or the acquisition of any license) of any rights in respect of any drug or other pharmaceutical product (and any related property or assets).", "snippet_links": [{"key": "payments-made", "type": "clause", "offset": [29, 42]}, {"key": "in-connection-with", "type": "clause", "offset": [43, 61]}, {"key": "product-research-and-development", "type": "clause", "offset": [89, 121]}, {"key": "collaboration-arrangements", "type": "clause", "offset": [125, 151]}, {"key": "the-closing", "type": "clause", "offset": [155, 166]}, {"key": "permitted-investment", "type": "clause", "offset": [174, 194]}, {"key": "other-acquisition", "type": "definition", "offset": [198, 215]}, {"key": "the-acquisition", "type": "clause", "offset": [242, 257]}, {"key": "in-respect-of", "type": "definition", "offset": [288, 301]}, {"key": "related-property", "type": "clause", "offset": [352, 368]}], "size": 11, "samples": [{"hash": "6JCWrzCSGeT", "uri": "/contracts/6JCWrzCSGeT#upfront-payments", "label": "Indenture (Biomarin Pharmaceutical Inc)", "score": 37.1149902344, "published": true}, {"hash": "mQJHemeJn7", "uri": "/contracts/mQJHemeJn7#upfront-payments", "label": "Indenture (Horizon Pharma PLC)", "score": 27.8145103455, "published": true}, {"hash": "1b2DuGdU3tq", "uri": "https://www.sec.gov/Archives/edgar/data/1492426/000119312519194847/d763841dex41.htm", "label": "Horizon Pharma (Horizon Therapeutics Public LTD Co)", "score": 21.5359344482, "published": false}], "hash": "aad499d88121ba376af53a1352cbc0f1", "id": 5}, {"snippet": "means any upfront or similar payments made during the period of twelve months ending on the Closing Date or arising thereafter in connection with any drug or pharmaceutical product research and development or collaboration arrangements.", "snippet_links": [{"key": "payments-made", "type": "clause", "offset": [29, 42]}, {"key": "period-of", "type": "definition", "offset": [54, 63]}, {"key": "twelve-months", "type": "clause", "offset": [64, 77]}, {"key": "the-closing-date", "type": "clause", "offset": [88, 104]}, {"key": "in-connection-with", "type": "clause", "offset": [127, 145]}, {"key": "product-research-and-development", "type": "clause", "offset": [173, 205]}, {"key": "collaboration-arrangements", "type": "clause", "offset": [209, 235]}], "size": 8, "samples": [{"hash": "k2Rupe3o4o2", "uri": "/contracts/k2Rupe3o4o2#upfront-payments", "label": "Credit Agreement (Halozyme Therapeutics, Inc.)", "score": 37.1286773682, "published": true}, {"hash": "dIB4sA3rNEH", "uri": "/contracts/dIB4sA3rNEH#upfront-payments", "label": "Credit Agreement (Halozyme Therapeutics, Inc.)", "score": 33.3915138245, "published": true}, {"hash": "axEvCq4eWFx", "uri": "/contracts/axEvCq4eWFx#upfront-payments", "label": "Credit Agreement (Halozyme Therapeutics, Inc.)", "score": 32.9917869568, "published": true}], "hash": "9a537aa7bde9ed15fde72d3322a2bdb9", "id": 6}, {"snippet": "has the meaning set forth in Section 6.1.", "snippet_links": [{"key": "section-61", "type": "clause", "offset": [29, 40]}], "size": 4, "samples": [{"hash": "8GRO6rsMFJY", "uri": "/contracts/8GRO6rsMFJY#upfront-payments", "label": "License and Option Agreement (Jazz Pharmaceuticals PLC)", "score": 36.5947990417, "published": true}, {"hash": "69j8zAQtheF", "uri": "/contracts/69j8zAQtheF#upfront-payments", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "8osnJoSuIky", "uri": "/contracts/8osnJoSuIky#upfront-payments", "label": "License and Option Agreement (Pfenex Inc.)", "score": 27.8555774689, "published": true}], "hash": "5fc9ad17e8642035860861b0e6bd9f1b", "id": 7}, {"snippet": "means First Upfront Payment, Second Upfront Payment, Third Upfront Payment, and the Forth Upfront Payment, collectively (or respectively, \u201cUpfront Payment\u201d).", "snippet_links": [{"key": "first-upfront-payment", "type": "definition", "offset": [6, 27]}, {"key": "second-upfront-payment", "type": "definition", "offset": [29, 51]}], "size": 4, "samples": [{"hash": "1l9zfgUO5ED", "uri": "/contracts/1l9zfgUO5ED#upfront-payments", "label": "Distribution Agreement (IceCure Medical Ltd.)", "score": 32.5564689636, "published": true}, {"hash": "d0YiALPHozC", "uri": "/contracts/d0YiALPHozC#upfront-payments", "label": "Distribution Agreement (IceCure Medical Ltd.)", "score": 32.5099258423, "published": true}], "hash": "e8e9c627d51fac0d95f8ba6df571d8ef", "id": 8}, {"snippet": "means an initial payment received by a Group Company from a third party as part of an intended ongoing arrangement in connection with a Research and Development Project, where such payment shall cover costs of the Research and Development Project already incurred and/or forecast to be incurred in the future by the relevant Group Company. \u201cValuation Event\u201d means, for the purposes of Article 4.2(b)(ii)(1) (Variable Remuneration): (a) the most recent issuance of shares subscribed by any third party(ies) for an amount of at least EUR 1,000,000 (one million euro); or (b) the most recent sale of existing shares to any third party(ies) for an amount of at least EUR 1,000,000 (one million euro); or (c) in case of event likely to have a material impact on the price per share of the investee since the events described in (a) and (b) above, a valuation prepared by an independent expert. \"Variable Remuneration\" has the meaning given to it in Article 4.2 (Variable Remuneration). \"Variable Remuneration Payment Date\" means 30 June of each year to fall after the publication of the Borrower's audited consolidated financial statements for the preceding financial year, up to (and including) the first of those dates to fall after the publication of the Borrower's audited consolidated financial statements for the year ended 31 December 2037. \"Voluntary Non EIB Prepayment\" means a voluntary prepayment by any Group Company (for the avoidance of doubt, prepayment shall include a repurchase, redemption or cancellation where applicable) of a part or the whole of any Non-EIB Financing where: (a) such prepayment is not made within a revolving credit facility (save for the cancellation of the revolving credit facility); or (b) such prepayment is not made out of the proceeds of a loan or other indebtedness having a term at least equal to the unexpired term of the Non-EIB Financing prepaid.", "snippet_links": [{"key": "received-by", "type": "definition", "offset": [25, 36]}, {"key": "a-group-company", "type": "definition", "offset": [37, 52]}, {"key": "a-third-party", "type": "clause", "offset": [58, 71]}, {"key": "in-connection-with", "type": "clause", "offset": [115, 133]}, {"key": "research-and-development-project", "type": "definition", "offset": [136, 168]}, {"key": "costs-of", "type": "clause", "offset": [201, 209]}, {"key": "the-research", "type": "clause", "offset": [210, 222]}, {"key": "the-future", "type": "clause", "offset": [298, 308]}, {"key": "relevant-group-company", "type": "definition", "offset": [316, 338]}, {"key": "valuation-event", "type": "clause", "offset": [341, 356]}, {"key": "article-42", "type": "clause", "offset": [385, 396]}, {"key": "variable-remuneration", "type": "definition", "offset": [408, 429]}, {"key": "most-recent", "type": "definition", "offset": [440, 451]}, {"key": "shares-subscribed", "type": "clause", "offset": [464, 481]}, {"key": "sale-of", "type": "clause", "offset": [589, 596]}, {"key": "existing-shares", "type": "clause", "offset": [597, 612]}, {"key": "in-case-of", "type": "clause", "offset": [704, 714]}, {"key": "likely-to-have", "type": "clause", "offset": [721, 735]}, {"key": "material-impact", "type": "definition", "offset": [738, 753]}, {"key": "price-per-share", "type": "definition", "offset": [761, 776]}, {"key": "the-events", "type": "clause", "offset": [799, 809]}, {"key": "prepared-by", "type": "clause", "offset": [854, 865]}, {"key": "independent-expert", "type": "clause", "offset": [869, 887]}, {"key": "remuneration-payment-date", "type": "definition", "offset": [991, 1016]}, {"key": "each-year", "type": "definition", "offset": [1035, 1044]}, {"key": "of-the-borrower", "type": "clause", "offset": [1075, 1090]}, {"key": "audited-consolidated-financial-statements", "type": "clause", "offset": [1093, 1134]}, {"key": "financial-year", "type": "definition", "offset": [1153, 1167]}, {"key": "the-year", "type": "definition", "offset": [1310, 1318]}, {"key": "voluntary-non-eib-prepayment", "type": "definition", "offset": [1344, 1372]}, {"key": "voluntary-prepayment", "type": "clause", "offset": [1382, 1402]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [1425, 1451]}, {"key": "where-applicable", "type": "clause", "offset": [1519, 1535]}, {"key": "any-non", "type": "clause", "offset": [1563, 1570]}, {"key": "save-for-the", "type": "clause", "offset": [1660, 1672]}, {"key": "the-revolving-credit-facility", "type": "clause", "offset": [1689, 1718]}, {"key": "a-loan", "type": "definition", "offset": [1779, 1785]}, {"key": "other-indebtedness", "type": "clause", "offset": [1789, 1807]}, {"key": "having-a", "type": "definition", "offset": [1808, 1816]}, {"key": "at-least-equal-to", "type": "definition", "offset": [1822, 1839]}, {"key": "the-non", "type": "clause", "offset": [1862, 1869]}], "size": 2, "samples": [{"hash": "5eI0TzorJ1e", "uri": "/contracts/5eI0TzorJ1e#upfront-payments", "label": "Finance Contract (Evotec SE)", "score": 33.6173858643, "published": true}, {"hash": "5yjATch1hRO", "uri": "/contracts/5yjATch1hRO#upfront-payments", "label": "Finance Contract (Evotec SE)", "score": 32.3579750061, "published": true}], "hash": "7b78afaffb0cbd2f44938044e227ae7b", "id": 9}, {"snippet": "is defined in Section 2.22(b).", "snippet_links": [{"key": "defined-in-section", "type": "clause", "offset": [3, 21]}], "size": 2, "samples": [{"hash": "fjJ9yUu7qP3", "uri": "/contracts/fjJ9yUu7qP3#upfront-payments", "label": "Credit Agreement (SMURFIT-STONE CONTAINER Corp)", "score": 22.2375087738, "published": true}, {"hash": "c2POHeRkSnp", "uri": "/contracts/c2POHeRkSnp#upfront-payments", "label": "Credit Agreement (Smurfit Stone Container Corp)", "score": 21.1505813599, "published": true}], "hash": "699924b66b2752ca018dd16594d6da6b", "id": 10}], "next_curs": "Cl0SV2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjkLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIZdXBmcm9udC1wYXltZW50cyMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"snippet": "means any upfront or similar payments made during the period of twelve months ending on the Closing Date or arising thereafter in connection with any drug or pharmaceutical product research and development or collaboration arrangements or the closing of any Drug Acquisition.", "size": 133, "title": "Upfront Payments", "id": "upfront-payments", "examples": ["All payments due to Reata hereunder, including <strong>Upfront Payments</strong>, Milestone Payments, Sales Royalties and Licensed Product supply payments, will be made by wire transfer of immediately available funds in United States dollars to a bank account or bank accounts designated by Reata.", "Such <strong>Upfront Payments</strong> shall be payable by KHK by wire transfer of immediately available funds in accordance with wire transfer instructions of DICERNA provided in writing to KHK prior to the Effective Date.", "For clarity, (i) Terumo will in no event be precluded from remedies available under Applicable Laws or this Agreement, (ii) Terumo will not be entitled to be reimbursed the remaining value of <strong>Upfront Payments</strong>, in the event of termination of this Agreement for any reason other than pursuant to Sections 12.2(b), (c), (e), or 12.2 (g) by Terumo and Section 12.2(d)(x) or (f) by IceCure (\u201cTermination Fee\u201d).", "In respect of each Miragen Target for which a Product License is or becomes effective, Miragen shall pay Santaris (a) [*] of all <strong>Upfront Payments</strong>; and (b) subject to Section 4.7(c), [*] of Sublicense Revenue (for clarity, excluding any Sublicense Royalties) that, in each case, Miragen receives from a Sublicensee.", "For clarity, (i) Terumo will in no event be precluded from remedies available under Applicable Laws or this Agreement, (ii) Terumo will not be entitled to be reimbursed the remaining value of <strong>Upfront Payments</strong>, in the event of termination of this Agreement for any reason other than pursuant to Sections 12.2(b), (c), (e), or 12.2 (g).", "In addition to the \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587 \u2587 Participants\u2019 <strong>Upfront Payments</strong>, the Enterprise shall also deposit all revenue that may be generated from the lease or operation of \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587 \u2587 Assets pursuant to Section 5.3 into the segregated accounts in proportion to the \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587 \u2587 Participant\u2019s NISP Participation Percentages.", "Joint Development Agreement No. IFPEN n\u00b02020-0085 JEPLAN shall open a dedicated bank account in Japan (the \u201cDedicated Bank Account\u201d) to receive all contributions from the Parties to JEPLAN in accordance with the Agreement (including the <strong>Upfront Payments</strong> from Axens as per Article 13.3.2) and make all CAPEX-related payments in relation with the Agreement.", "In the event that Dermavant or its Affiliates grant any sublicense to any Third Party under the license granted to it under Section 2.1(a), Dermavant shall pay to Portola [***] of all <strong>Upfront Payments</strong> received from its sublicensee.", "Notwithstanding anything provided in Article 7.4, Terumo shall make the <strong>Upfront Payments</strong> after deducting the applicable taxes.", "The Parties shall provide each other with reporting regarding such transactions and activities (including regarding information with respect to Sales of Qualified Seats, [************************************], Sales of Licensed Products, <strong>Upfront Payments</strong>, Recurring Payments, Clawback Credits, and License Fees), as applicable, in a form, and at a frequency, agreed by the Parties (which agreement shall not be unreasonably withheld, conditioned or delayed)."], "related": [["upfront-payment", "Upfront Payment", "Upfront Payment"], ["upfront-fees", "Upfront Fees", "Upfront Fees"], ["filot-payments", "FILOT Payments", "FILOT Payments"], ["earnout-payments", "Earnout Payments", "Earnout Payments"], ["installment-payments", "Installment Payments", "Installment Payments"]], "related_snippets": [], "updated": "2026-04-18T05:49:41+00:00"}, "json": true, "cursor": ""}}